At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
In Brief
A Phase 1 clinical trial evaluating Laboratory Biomarker Analysis, Palliative Radiation Therapy, and 2 other interventions for Pleural Malignant Mesothelioma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma. Radiation therapy uses high energy radiation to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after radiation therapy may kill more tumor cells.
Study Details
Timeline
Interventions
Correlative studies
Undergo palliative radiation therapy
Given IV
Undergo hemithoracic radiation therapy